551 related articles for article (PubMed ID: 25213048)
21. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.
Hanania NA; Feldman G; Zachgo W; Shim JJ; Crim C; Sanford L; Lettis S; Barnhart F; Haumann B
Chest; 2012 Jul; 142(1):119-127. PubMed ID: 22241764
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
[TBL] [Abstract][Full Text] [Related]
25. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
Zheng J; de Guia T; Wang-Jairaj J; Newlands AH; Wang C; Crim C; Zhong N
Curr Med Res Opin; 2015 Jun; 31(6):1191-200. PubMed ID: 25830381
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
Chen X; Zheng X; Jiang J; Hu P; Wu K; Zhuang L; Liu L; Du X; Kempsford R; Allen A
Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
Ishiura Y; Fujimura M; Shiba Y; Ohkura N; Hara J; Kasahara K
Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
[TBL] [Abstract][Full Text] [Related]
30. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.
Bleecker ER; Bateman ED; Busse WW; Woodcock A; Frith L; House KW; Jacques L; Davis AM; Haumann B; Lötvall J
Ann Allergy Asthma Immunol; 2012 Nov; 109(5):353-358.e4. PubMed ID: 23062392
[TBL] [Abstract][Full Text] [Related]
31. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
Kempsford R; Allen A; Bareille P; Hamilton M; Cheesbrough A
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):2-11. PubMed ID: 27127998
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial.
Woodcock A; Bleecker ER; Lötvall J; O'Byrne PM; Bateman ED; Medley H; Ellsworth A; Jacques L; Busse WW
Chest; 2013 Oct; 144(4):1222-1229. PubMed ID: 23846316
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.
Wolthers OD
Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):144-50. PubMed ID: 26581314
[TBL] [Abstract][Full Text] [Related]
34. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.
Allen A; Schenkenberger I; Trivedi R; Cole J; Hicks W; Gul N; Jacques L
Clin Respir J; 2013 Oct; 7(4):397-406. PubMed ID: 23578031
[TBL] [Abstract][Full Text] [Related]
35. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma.
Oliver A; VanBuren S; Allen A; Hamilton M; Tombs L; Inamdar A; Kempsford R
Clin Ther; 2014 Jun; 36(6):928-939.e1. PubMed ID: 24793536
[TBL] [Abstract][Full Text] [Related]
36. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.
Bateman ED; O'Byrne PM; Busse WW; Lötvall J; Bleecker ER; Andersen L; Jacques L; Frith L; Lim J; Woodcock A
Thorax; 2014 Apr; 69(4):312-9. PubMed ID: 24253831
[TBL] [Abstract][Full Text] [Related]
37. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
Lee L; Kerwin E; Collison K; Nelsen L; Wu W; Yang S; Pascoe S
Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
[TBL] [Abstract][Full Text] [Related]
38. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.
Lee LA; Yang S; Kerwin E; Trivedi R; Edwards LD; Pascoe S
Respir Med; 2015 Jan; 109(1):54-62. PubMed ID: 25452139
[TBL] [Abstract][Full Text] [Related]
39. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study.
Svedsater H; Jones R; Bosanquet N; Jacques L; Lay-Flurrie J; Leather DA; Vestbo J; Collier S; Woodcock A
Respir Med; 2018 Aug; 141():198-206. PubMed ID: 30053967
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.
Covelli H; Pek B; Schenkenberger I; Scott-Wilson C; Emmett A; Crim C
Int J Chron Obstruct Pulmon Dis; 2016; 11():1-12. PubMed ID: 26730183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
